Kornimate/medical-research-clean huggingface dataset:
ivf versus lod in women with cc resistant pcos

Conditions: Infertility; Polycystic Ovarian Syndrome

Summary: the purpose of this study is to compare the efficacy of in vitro fertilization (ivf) versus laparoscopic ovarian drilling (lod) in infertile women having clomiphene citrate (cc) resistant polycystic ovarian syndrome (pcos).

women will be randomly divided into two groups; ivf group and lod group. women in the ivf group will undergo one full ivf cycle. women in the lod group will be subjected to lod followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months.

Eligibility criteria:
inclusion criteria: * infertile women with pcos as defined by the rotterdam criteria. * cc resistance (defined as failure of ovulation after receiving 150 mg/day of cc for 5 consecutive days per cycle, for at least 3 consecutive cycles). exclusion criteria: * age \ 35 years. * presence of any infertility factor other than anovulatory pcos. * previous history of ovarian surgery or surgical removal of one ovary. * previous exposure to cytotoxic drugs or pelvic irradiation. * oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months. * metabolic or hormonal abnormalities.

Keywords: pcos clomiphene citrate resistant lod ivf
conventional dose versus high dose sequential chemotherapy for poor prognosis germ cell tumors

Conditions: Testicular Neoplasms; Germ Cell Tumors

Summary: the purpose of this study is to determine whether the use of a sequential high dose chemotherapy is more effective than conventional dose (i.e. 4 cycles of cisplatin, etoposide, and bleomycin \[peb\]) in patients with metastatic poor prognosis germ cell tumors.


Eligibility criteria:
inclusion criteria: * clinical or histological diagnosis of germ cell tumors * metastatic disease * poor prognostic category according to the international germ cell collaborative group (igcccg) classification * no prior chemotherapy for metastatic disease exclusion criteria: * unwillingness to accomplish the study procedures * any existing co-morbidity that could limit the administration of high dose chemotherapy * any psychiatric disorder that could impact on the study compliance
contrast ultrasound in the surveillance of endovascular abdominal aortic aneurysm repair

Conditions: Endovascular Abdominal Aortic Aneurysm Repair

Summary: the purpose of this study is to support the suspected expectation that contrast enhanced ultrasound (cus) detects all endoleaks that have been detected by computed tomography (ct), and also find a number of leaks missed by ct. the investigators' primary goal is to detect no difference between ct and cus and provide evidence that cus is a possible alternative to ct.


Eligibility criteria:
inclusion criteria: * all patients who underwent evar at the ottawa hospital and currently under post-evar surveillance at the ottawa hospital. exclusion criteria: * unable to consent for injection of contrast * unable to acquire iv access * right-to-left, bi-directional, or transient right-to-left cardiac shunts * severe pulmonary disease * previous hypersensitivity to definity® or its components * unable to be followed as a outpatient by the vascular diagnostic center

Keywords: endovascular abdominal aortic aneurysm repair surveillance evar ct scan endoleaks contrast enhanced ultrasound definity aaa imaging no endoleaks
study to evaluate the effects of acetylsalicylic acid (asa) on niaspan®-induced flushing in subjects with dyslipidemia

Conditions: Dyslipidemia

Summary: the primary purpose of this study was to assess the effect of aspirin (asa) on niacin extended-release (ner)-induced flushing in subjects with dyslipidemia.


Eligibility criteria:
inclusion criteria: * subject must be 18 years of age or older. * if female, subject is either not of childbearing potential, defined as postmenopausal for at least one year or surgically sterile, or is of childbearing potential and must agree to practice birth control for the duration of the study. * have dyslipidemia as demonstrated by laboratory results. exclusion criteria: * have glycosylated hemoglobin (hba1c) \>/= 9.0%. * have nephrotic syndrome, dysproteinemias, or severe renal failure (glomerular filtration rate \[gfr\] \< 30 ml/minute, as calculated from creatinine clearance). * have had unstable angina or an acute myocardial infarction (mi) within three months of the screening visit. * have had severe peripheral artery disease as evidenced by intermittent claudication within three months of the screening visit. * have had uncontrolled cardiac arrhythmias within three months of the screening visit. * have symptomatic heart failure defined as dyspnea at rest or with exertion (mild peripheral edema is not exclusionary). * have a systolic blood pressure measurement of \> 180 mmhg or a diastolic blood pressure measurement of \> 110 mmhg at the screening or baseline visit. * have active gout or uric acid \>/= 11 mg/dl. * have a history of hepatitis (acute or chronic), obstructive liver disease, or alanine aminotransferase (alt; serum glutamic pyruvic transaminase \[sgpt\]) or aspartate aminotransferase (ast; serum glutamic oxaloacetic transaminase \[sgot\]) values \>/= 1.3 times the upper limit of normal (uln) at the screening visit. * have creatine phosphokinase (cpk) \>/= 3 x uln at the screening visit. * have used an investigational study drug or participated in an investigational study within 30 days of the screening visit. * have a health condition or laboratory abnormality (inclusive of clinically significant laboratory results at screening visit), which, in the opinion of the investigator, may be adversely affected by the procedures or study medications in this study.
persona tka with iassist knee system and iassist knee system

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to compare the accuracy of knee component alignment between patients operated with iassist knee (investigational group) versus patients operated without iassist knee (control group) using the same implant system.

objective： to compare the accuracy of knee component alignment between patients operated with iassist knee (investigational group) versus patients operated without iassist knee (control group) using the same implant system. endpoint： primary： the alignment accuracy of the knee femoral and tibial components at 6 months for the investigational group compared to the control group. secondary：health status after tka, operating room efficiency and complication rate after tka for the investigational group compared to the control group.

Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, a patient must meet all of the following criteria. * knee (either unilateral or bilateral) osteoarthritis (varus deformity only) * male or female * at least 20 years of age * patients willing to return for follow-up evaluations. study specific requirements for principal investigator/site * principal investigator (pi) must have experience of at least 5 tkas of iassist knee with persona and persona conventional instrument system before any study specific activities. * site has sufficient resources to take limb ct scanning at 6 months follow-up visit. exclusion criteria: absolute contraindications include: * knee degenerative diseases other than knee osteoarthritis (such as necrosis/rheumatoid arthritis) * too severe oa deformation (fta: \> 190 degrees/\< 175 degrees) * active infection (or within 6 weeks after infection) * sepsis * osteomyelitis * any type of implant is inserted in the affected side of lower extremity * hip and/or foot disease on the affected side additional contraindications include: * uncooperative patient or patient with neurologic disorders who are incapable of following directions * diagnosed osteoporosis or osteomalacia * metabolic disorders which may impair bone formation * distant foci of infections which may spread to the implant site * rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram * vascular insufficiency, muscular atrophy or neuromuscular disease.
paracetamol and pharmacogenetic

Conditions: Healthy

Summary: recent works has emphasized that the mechanism of action of paracetamol analgesic depend on its metabolism in the body, since a breakdown product of paracetamol, the am404 is now considered the analgesic metabolite of paracetamol suggesting as paracetamol may be a pro-drug. indeed, it has been shown that paracetamol may have a deleterious effect, especially in vulnerable populations (hepatic insufficiency, elderly). first results showed a very significant decrease in sulfatation and gluthatione and increased phase 1 metabolism of acetaminophen, which involves enzymes such as cytochrome p450. multifactorial causes, combining nutrition (depletion of sulfur amino acids), increased detoxification of toxic metabolites of paracetamol, stress or trauma are discussed to explain the results. clinical studies showed a great variability of pain assessment by patients and variability in the metabolic response of paracetamol. genetic factors probably play a role remains largely unknown. the review of the literature on genetic polymorphism shows the involvement of a number of enzymes that are well known, predominantly on the metabolism of acetaminophen liver, but without connection with its analgesic effect. this is a critical missing link in the understanding of the analgesic effect of paracetamol.

randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week. the evaluation criterion is the difference in areas under the curve of pain thresholds to thermal and mechanical stimulations test

Eligibility criteria:
inclusion criteria: * healthy volunteers * males * aged between 18 and 30 years exclusion criteria: * subject without cons-indications of paracetamol

Keywords: pharmacogenetic of paracetamol pain threshold
profile - evaluation of qol and pro outcomes in patients taking fingolimod

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: multi centre, prospective, non interventional study in 200-240 uk relapsing remitting multiple sclerosis patients. patients will complete questionnaires at baseline, 3, 6 and 12 months.

multi centre, prospective, non interventional study in 200-240 uk relapsing remitting multiple sclerosis patients assessing the change in qol and pro outcome measures from baseline to 12 months after starting fingolimod. patients will complete 4 questionnaires at baseline (prior to first fingolimod dose), then repeat them at 3, 6 and 12 month intervals via post.

Eligibility criteria:
inclusion criteria: patients prescribed gilenya within the eu licence no previous exposure to gilenya patient's hcp considers patient able to complete study questionnaires patient is between 18-55 years of age - exclusion criteria: there are no exclusion criteria for this study. -
evaluation of sarcopenia and related factors in patients diagnosed with psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: the purpose of the study is identify the prevalence of sarcopenia and its associated factors in patients with psoriatic arthritis. furthermore, we aimed to investigate the predictive contribution of usg in diagnosing sarcopenia by assessing the thickness of the rectus femoris, vastus intermedius, and quadriceps muscles in patients with psoriatic arthritis.

after being informed about study and potential risk, all patient and giving written informed consent will undergo screnneing determite eligibility for study entire. participants who agree to take part in the study and sign the informed consent form will be divided into two groups: patients and healthy volunteers. the patients will undergo a rheumatological examination, and sarcopenia screening will be conducted for both groups. additionally, the quadriceps muscle thickness of both groups will be measured.

Eligibility criteria:
inclusion criteria: * diagnosed with psoriatic arthritis according to caspar criteria at least 1 year ago * between 18 and 65 years old * normal cognitive functions * agrees to participate in the study * no changes in medical treatment for psoriatic arthritis in the last 3 months exclusion criteria: * those with neurological diseases * those with hip dysplasia * those with upper and lower extremity deformities * those with upper and lower extremity joint arthroplasty * those with arthritis and deformities in the hands * those with lumbar stabilization * those with cognitive impairment preventing participation in the study * those with body weight beyond the device\&#39;s measurement capacity * those who do not agree to participate in the study

Keywords: rheumatic disease sarcopenia ultrasonography
a cardiac disease quality of life study

Conditions: Hypertrophic Obstructive Cardiomyopathy; Thoracic Aortic Dilatation; Heart Disease Caused by Ionising Radiation; Quality of Life

Summary: a prospective, longitudinal, non-comparator, non-randomized observational cohort study to assess the quality of life in adult patients affected by hypertrophic cardiomyopathy and thoracic aortic dilatations who are not amenable to surgery, as well as those affected radiation-induced cardiac disease caused by radiation therapy.

while physicians and patients may be aware of the physical limitations that result from a diagnosis of hypertrophic cardiomyopathy (hcm), thoracic aortic dilatation (tad) or radiation-induced heart disease (rihd), there is little research on the impact on quality of life from the limitations imposed with these diagnosis. this study aims to address these unknowns in patients with hcm or tad as well as radiation-induced heart disease in first-time patients at the cleveland clinic. knowledge gained from this study will provide us the ability for better management of the chronic impacts of the disease by identifying potential risk factors of low quality of life or changes in quality of life over time. this is a prospective, longitudinal, non-comparator, non-randomized survey study describing qol outcomes for patients with hcm, tad, or rihd. patients being seen for the first time at the cleveland clinic for cardiac disease with no previous or scheduled surgery for hcm or tad will electronically complete a cardiac quality of life survey at 3 time points (baseline, 3 month \& 9 month). the cardiac quality of life survey measures the participant's health status in five domains - global, physical, emotional, social, and spiritual - as well as self-efficacy and resilience.

Eligibility criteria:
inclusion criteria: * patients aged 18-70 at time of consent with a confirmed diagnosis of hcm, tad, and/or rihd being seen at cc main campus for a comprehensive clinical cardiac evaluation (i.e. physician, surgeon, nurse practitioner, geneticist, testing, imaging, etc) to define treatment plan for either diagnosis as per cleveland clinic provider. * patient or an individual in their social support network has the equipment (phone, computer, tablet) and internet connection to complete the emailed follow-up questionnaires. exclusion criteria: * previously had surgery or plans to have surgery (full/mini sternotomy or endovascular) in the next nine months for hcm or tad. * inability or unwillingness to comply with study requirements in the opinion of the investigator. * inability to provide informed consent.
the temporally interfering in patients with disorders of consciousness

Conditions: Disorders of Consciousness

Summary: this project will help the patient recover consciousness by giving ti (temporally interfering) treatment


Eligibility criteria:
inclusion criteria: in accordance with the international diagnostic criteria for mcs formulated by giacino in 2002 or the diagnostic criteria for uws proposed by laureys in 2010; patients with disease duration ≥28 days and unconscious improvement tendency in the past one month; no use of any sedative drugs or antiepileptic drugs (sodium or calcium channel blockers) in the past 1 month; stable vital signs; no obvious brain edema, hydrocephalus, and severe brain atrophy; age from 18 to 70 years old; informed consent was obtained from the patients' family members. exclusion criteria: previous history of neurological or psychiatric disorders; previous history of traumatic brain injury; history of cancer; taking sedative drugs or antiepileptic drugs in the past 1 month; unstable vital signs; skull defect; the patients' family members did not sign the informed consent.
psychometric properties of the turkish version of the hana in tension type headache

Conditions: Tension Type Headache

Summary: individuals with tension type headache


Eligibility criteria:
inclusion criteria: * having a diagnosis of tension-type headache, * being between 18 and 65 years of age. exclusion criteria: * having a diagnosis of any headache disorder other than tension-type headache, * having a history of any systemic disease, such as malignancy, inflammatory conditions, acute fractures, surgical history, or neurological, psychological, or rheumatological disorders.

Keywords: headache needs assessment survey tension type headache turkish
advair® diskus® versus serevent® diskus® for chronic obstructive pulmonary disease exacerbations

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this study evaluates the effect of two medicines on copd (chronic obstructive pulmonary disease) exacerbations. this study will last up to 56 weeks, and subjects will visit the clinic 10 times. subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. all study related medicines and medical examinations will be provided at no cost. the two drugs used in this study have been approved by fda for use in patients with copd.

a randomized, double-blind, parallel group, 52-week study to compare the effect of the fluticasone propionate/salmeterol diskus combination product 250/50mcg bid with salmeterol diskus 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (copd)

Eligibility criteria:
inclusion criteria: * diagnosis of copd. * current or previous cigarette smokers with a smoking history of at least 10 pack-years. * history of at least 1 copd exacerbation in the 12 months prior to screening. * forced expiratory volume in one second (fev1) of less than or equal to 50% of predicted normal. exclusion criteria: * diagnosis of asthma. * additional respiratory disorders other than copd (eg, sarcoidosis, alpha-1 antitrypsin deficiency, cystic fibrosis, or active tuberculosis). * concurrent use of long-acting beta-agonists, long-acting anticholinergics, inhaled and oral corticosteroids, theophylline, investigational medications, ritonavir, and anti-leukotrienes. * lung resection surgery within 1 year of screening. * abnormal and clinically significant ecg findings at screening. * other inclusion and exclusion criteria will be evaluated at the first study visit.

Keywords: breathing exacerbation chronic obstructive pulmonary disease
near infrared spectroscopy to determine patent ductus arteriosus closure

Conditions: Patent Ductus Arteriosus

Summary: using cerebral and renal near infrared spectroscopy monitoring to determine pda closure in preterm infants after completing medical treatment for a hemodynamically significant pda.


Eligibility criteria:
inclusion criteria: * preterm infants less than 32 weeks gestation exclusion criteria: * infection, congenital heart disease, syndromic anomalies, and perinatal asphyxia.
vaginal diazepam for the treatment of female pelvic pain

Conditions: Pelvic Floor Disorders; Pelvic Pain

Summary: to determine the efficacy of intravaginal diazepam for the treatment of pelvic pain associated with pelvic floor hypertonic disorder.

women who are asked to participate will already be receiving a standard conservative therapy consisting of a psyllium-based bowel regimen, heat therapy, pelvic stretching exercises, and kegel exercises. participants will randomly be assigned by a computer-derived random number sequence (after pregnancy is ruled out) to either the treatment group (intravaginal diazepam) or the placebo group investigators and patients will be blinded to group assignment. the placebo or diazepam tablet will be distributed to the participant in the examining room on the day of allocation. the participant will be instructed to insert the diazepam or placebo tablet into her vagina at home. the treatment group will insert the diazepam 10 mg vaginal tablet 1-2 times daily as needed in addition to the standard conservative therapy. the placebo group will receive the standard conservative therapy, and an intravaginal tablet (visually indistinguishable from diazepam) commercially produced by the university pharmacy. after 4 weeks, patients from either group will have the option of enrolling into a standard routine program (not research) of comprehensive pelvic floor rehabilitation therapy. the visual analog pain scale, pelvic floor distress inventory-20 questionnaire, mcgill pain questionnaire and global response assessment will be completed by the participant at the initial visit, 4 weeks, 8 weeks and 12 weeks. participants will be given the option of choosing one or more methods for returning questionnaires: electronic mail, self-addressed home envelope, or telephone call.

Eligibility criteria:
inclusion criteria: * age 18 years old * primary complaint of acute or chronic pelvic pain with or without dyspareunia * physical exam findings consistent with levator muscle spasm * capable of inserting tablet in vagina without use of applicator. exclusion criteria: * chronic narcotic use * non-english speaking * currently serving a prison sentence * stage iii or greater vaginal prolapse * allergies or contraindications to benzodiazepines * pregnant or breastfeeding * currently receiving comprehensive pelvic floor rehabilitation therapy and/or vaginal valium therapy * unwilling or incapable of inserting tablet in vagina without applicator.

Keywords: high-tone pelvic floor dysfunction spasm pelvic pain diazepam female randomized trial
evaluating treatment response in laryngo-pharyngeal reflux

Conditions: Laryngo-pharyngeal Reflux

Summary: although laryno-pharyngeal reflux (lpr) and gastroesophageal reflux disease (gerd) differ in symptoms and treatment, they are diagnosed by the same standard 24-hour ph monitoring system which measures liquid reflux in the esophagus. the investigators are evaluating a new 24-hour pharyngeal ph monitoring system by restech which can measure acid exposure in the airway and can be used specifically for lpr diagnosis. the purpose of this study is to determine whether the restech device is more effective than standard ph monitoring in predicting the response to proton pump inhibitor (ppi) acid suppression therapy using dexlansoprazole in patients with symptoms and/or manifestations of lpr.


Eligibility criteria:
inclusion criteria: * age 18 years old or above * have a clinical diagnosis of lpr * able and willing to provide consent exclusion criteria: * history of any previous anti-reflux operation or procedure * history of pharyngeal or laryngeal surgery * history of larngeal or hypolaryngeal neoplasm * allergy or significant adverse reaction to ppi * patient on ppi therapy within 4 weeks prior to enrollment * a cumulative history of ppi therapy equal to or greater than 3 months * history of noncompliance with medication or study protocols * enrolled in another clinical trial using investigational medications

Keywords: lpr gerd